141 related articles for article (PubMed ID: 26276747)
1. ERβ expression and breast cancer risk prediction for women with atypias.
Hieken TJ; Carter JM; Hawse JR; Hoskin TL; Bois M; Frost M; Hartmann LC; Radisky DC; Visscher DW; Degnim AC
Cancer Prev Res (Phila); 2015 Nov; 8(11):1084-92. PubMed ID: 26276747
[TBL] [Abstract][Full Text] [Related]
2. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer.
Fabian CJ; Kamel S; Zalles C; Kimler BF
J Cell Biochem Suppl; 1996; 25():112-22. PubMed ID: 9027607
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor expression in atypical hyperplasia: lack of association with breast cancer.
Barr FE; Degnim AC; Hartmann LC; Radisky DC; Boughey JC; Anderson SS; Vierkant RA; Frost MH; Visscher DW; Reynolds C
Cancer Prev Res (Phila); 2011 Mar; 4(3):435-44. PubMed ID: 21209395
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
5. Stratification of breast cancer risk in women with atypia: a Mayo cohort study.
Degnim AC; Visscher DW; Berman HK; Frost MH; Sellers TA; Vierkant RA; Maloney SD; Pankratz VS; de Groen PC; Lingle WL; Ghosh K; Penheiter L; Tlsty T; Melton LJ; Reynolds CA; Hartmann LC
J Clin Oncol; 2007 Jul; 25(19):2671-7. PubMed ID: 17563394
[TBL] [Abstract][Full Text] [Related]
6. Breast cytology and biomarkers obtained by random fine needle aspiration: use in risk assessment and early chemoprevention trials.
Fabian CJ; Zalles C; Kamel S; Zeiger S; Simon C; Kimler BF
J Cell Biochem Suppl; 1997; 28-29():101-10. PubMed ID: 9589354
[TBL] [Abstract][Full Text] [Related]
7. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.
Roger P; Sahla ME; Mäkelä S; Gustafsson JA; Baldet P; Rochefort H
Cancer Res; 2001 Mar; 61(6):2537-41. PubMed ID: 11289127
[TBL] [Abstract][Full Text] [Related]
8. Expression of ERalpha and ERbeta in lobular carcinoma in situ.
Middleton LP; Perkins GH; Tucker SL; Sahin AA; Singletary SE
Histopathology; 2007 Jun; 50(7):875-80. PubMed ID: 17543077
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein90 in lobular neoplasia of the breast.
Zagouri F; Nonni A; Sergentanis TN; Papadimitriou CA; Michalopoulos NV; Lazaris AC; Patsouris E; Zografos GC
BMC Cancer; 2008 Oct; 8():312. PubMed ID: 18957107
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma.
Chakravarty D; Srinivasan R; Ghosh S; Rajwanshi A; Gopalan S
Appl Immunohistochem Mol Morphol; 2008 Dec; 16(6):535-42. PubMed ID: 18931615
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer risk associated with estrogen receptor expression in epithelial hyperplasia lacking atypia and adjacent lobular units.
Gobbi H; Dupont WD; Parl FF; Schuyler PA; Plummer WD; Olson SJ; Page DL
Int J Cancer; 2005 Feb; 113(5):857-9. PubMed ID: 15499614
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor beta in breast cancer: associations between ERbeta, hormonal receptors, and other prognostic biomarkers.
Choi Y; Pinto M
Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):19-24. PubMed ID: 15722789
[TBL] [Abstract][Full Text] [Related]
13. The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR.
Green AR; Young P; Krivinskas S; Rakha EA; Claire Paish E; Powe DG; Ellis IO
Histopathology; 2009 Mar; 54(4):419-27. PubMed ID: 19309393
[TBL] [Abstract][Full Text] [Related]
14. Circulating 27-hydroxycholesterol and breast cancer tissue expression of CYP27A1, CYP7B1, LXR-β, and ERβ: results from the EPIC-Heidelberg cohort.
Le Cornet C; Walter B; Sookthai D; Johnson TS; Kühn T; Herpel E; Kaaks R; Fortner RT
Breast Cancer Res; 2020 Feb; 22(1):23. PubMed ID: 32075687
[TBL] [Abstract][Full Text] [Related]
15. Frequent loss of estrogen receptor-beta expression in prostate cancer.
Horvath LG; Henshall SM; Lee CS; Head DR; Quinn DI; Makela S; Delprado W; Golovsky D; Brenner PC; O'Neill G; Kooner R; Stricker PD; Grygiel JJ; Gustafsson JA; Sutherland RL
Cancer Res; 2001 Jul; 61(14):5331-5. PubMed ID: 11454669
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target.
Skliris GP; Leygue E; Watson PH; Murphy LC
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):1-10. PubMed ID: 18243688
[TBL] [Abstract][Full Text] [Related]
17. Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia.
Santisteban M; Reynolds C; Barr Fritcher EG; Frost MH; Vierkant RA; Anderson SS; Degnim AC; Visscher DW; Pankratz VS; Hartmann LC
Breast Cancer Res Treat; 2010 Jun; 121(2):431-7. PubMed ID: 19774459
[TBL] [Abstract][Full Text] [Related]
18. Enterolactone is differently associated with estrogen receptor beta-negative and -positive breast cancer in a Swedish nested case-control study.
Sonestedt E; Borgquist S; Ericson U; Gullberg B; Olsson H; Adlercreutz H; Landberg G; Wirfält E
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3241-51. PubMed ID: 18990767
[TBL] [Abstract][Full Text] [Related]
19. Association of Aromatase With Bladder Cancer Stage and Long-Term Survival: New Insights Into the Hormonal Paradigm in Bladder Cancer.
Nguyen DP; O'Malley P; Al Hussein Al Awamlh B; Furrer MA; Mongan NP; Robinson BD; Wang GJ; Scherr DS
Clin Genitourin Cancer; 2017 Apr; 15(2):256-262.e1. PubMed ID: 27324053
[TBL] [Abstract][Full Text] [Related]
20. Investigation of immunohistochemical ERα, ERβ and ERβcx expressions in normal and neoplastic breast tissues.
Bozkurt KK; Kapucuoğlu N
Pathol Res Pract; 2012 Mar; 208(3):133-9. PubMed ID: 22336175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
